Tirzepatide May Switch On Brown Fat in Mice

A new animal study points to a possible second mechanism behind tirzepatide's effects on weight and blood sugar. Researchers at the University of Barcelona, working with the Sant Joan de Déu Research Institute and CIBEROBN, gave obese mice on a high fat diet either tirzepatide or a matched, reduced amount of food without the drug. Comparing the two groups let them separate effects caused directly by the compound from effects caused simply by eating less.

The drug treated mice showed activated brown adipose tissue, a type of fat that burns energy rather than storing it. According to the University of Barcelona report, this activation was linked to increased calorie burning capacity and to production of batokines, signaling molecules from brown fat that appear to benefit metabolism. Past attempts to activate brown fat with other drugs often ran into cardiovascular side effects, but the researchers say tirzepatide did not show that problem in this model and was instead associated with cardiovascular benefits.

Tirzepatide is approved for weight management and for type 2 diabetes in humans, but this particular brown fat finding comes only from mice. The researchers were explicit that species differences in metabolism and fat distribution mean the result needs confirmation through further clinical research in people before any conclusions are drawn about how the drug works in humans.

This article is for education only. It is not medical advice. Compounds discussed here are sold for research purposes. Talk to a licensed clinician before making health decisions.